Optune versus salvage chemotherapy in glioblastoma
Thursday, January 28, 2016
Susan Panullo, M.D., director of Neurosurgical Radiosurgery at the Weill Cornell Brain and Spine Center, speaks to Targeted Oncology about the improvement in quality of life in patients with glioblastoma treated with Optune (NovoTTF-100A).
Panullo says patients treated with Optune versus patients treated with salvage chemotherapy both lived the same amount of time, with the former's quality of life being much better than the latter's.
Most recently, Optune in combination with adjuvant temozolomide received FDA approval as a treatment for patients with newly diagnosed glioblastoma multiforme (GBM) following surgery, chemotherapy, and radiation therapy.